Dermatology drugs are medications used to treat a wide range of skin conditions. They are tailored to address dermatological issues such as pigmentation disorders, acne, wrinkles, Psoriasis, etc. These drugs are formulated to target and alleviate particular skin concerns, providing therapeutic benefits. By effectively managing and enhancing the health and appearance of the skin, dermatology drugs play a pivotal role in helping individuals overcome diverse dermatological challenges, resulting in healthier and rejuvenated skin.
According to Data Bridge Market Research, the Dermatology Drugs Market is expected to grow with a CAGR of 8.2% in the forecast period of 2022 to 2029.
“Surging prevalence of skin diseases drives the market”
The market growth is predominantly propelled by the rising incidence of skin cancer and skin disorders such as acne, vitiligo, and dermatosis, which generates a demand for efficient drug treatments. Additionally, the presence of cost-effective surgical interventions for common dermatological conditions, combined with the accessibility and affordability of these drugs, is anticipated to bolster market expansion. Collectively, these factors drive the growth of the dermatological treatments and medications market, meeting the increasing need for effective solutions in dermatology.
What restraints the growth of the dermatology drugs market?
“Patient non-adherence to treatment hampers the market”
Patient non-adherence to treatment regimens constrains the growth of the dermatology drugs market. Non-adherence occurs when patients deviate from prescribed medication schedules or fail to complete the full treatment course, resulting in suboptimal outcomes and reduced efficacy. Overcoming this challenge and promoting market expansion requires improving patient education, enhancing communication between healthcare providers and patients, and developing innovative strategies to encourage treatment adherence. These efforts are vital for ensuring better patient outcomes and driving the growth of the dermatology drugs market.
Segmentation: U.S. Dermatology Drugs Market
The dermatology drugs market is segmented on the basis of drug class, drug type, prescription mode, indication, route of administration, end user and distribution channel.
- On the basis drug class, the dermatology drugs market has been segmented into corticosteroids, retinoid, monoclonal antibodies, antibiotics agent, antiviral agents, antifungal drugs, antihistamines drugs, immunosuppressive drugs, others.
- On the basis of drug type, the dermatology drugs market has been segmented into branded, generics.
- On the basis of prescription mode, the dermatology drugs market has been segmented into prescription based drugs, and over-the-counter drugs.
- On the basis of indication, the dermatology drugs market has been segmented into infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer, and others.
- On the basis of route of administration, the dermatology drugs market has been segmented into topical, oral, and parenteral.
- On the basis of end user, the dermatology drugs market has been segmented into homecare, hospitals, dermatology clinics, others.
- On the basis of distribution channel, the dermatology drugs market has been segmented into retail pharmacy, hospitals pharmacy, online pharmacy, others.
To know more about the study visit, https://www.databridgemarketresearch.com/pt/reports/us-dermatology-drugs-market
Recent Developments
- In July 2021, to expand its product portfolio, Sol-Gel Technologies, Ltd. announced the approval of TWYNEO cream by the US Food and Drug Administration for treating acne vulgaris in adults and paediatric patients aged 9 years and up.
- In June 2021, Galderma announced two S-year agreements with Sol-Gel Technologies itd, with the goal of commercialising EPSOLAY and TWYNEO in the United States while maintaining its brand position as a leader in this region.
The Prominent Key Players Operating in the Dermatology Drugs Market Include:
- Novartis AG (U.S.)
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Almirall, S.A (U.K.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- UCB S.A. (Belgium)
- Glenmark Pharmaceuticals Limited (India)
- Tolmar Pharmaceuticals, Inc. (U.S.)
- GlaxoSmithKline plc. (U.K.)
- Galderma Laboratories, L.P. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- LEO Pharma A/S (Denmark)
- MELINTA THERAPEUTICS, INC. (U.S.)
- Mayne Pharma Group Limited (Australia)
- BIOFRONTERA AG (Germany)
- AbbVie Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of dermatology drugs market companies contact, https://www.databridgemarketresearch.com/pt/contact
Research Methodology: Global Dermatology Drugs Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
